PRESS RELEASE

OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025 OMS1620 is advancing through IND-enabling studies for diseases associated with…Read More

You might also be interested in reading What XRP promised, this new token delivers: A deep dive into XRP 2.0.